

# Alzheimer's Disease - Pipeline Review, H1 2020

<https://marketpublishers.com/r/A987E347D4BEN.html>

Date: February 2020

Pages: 1716

Price: US\$ 2,500.00 (Single User License)

ID: A987E347D4BEN

## Abstracts

Alzheimer's Disease - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H1 2020, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development

by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 20, 64, 74, 4, 320, 129 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 100 and 45 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

Introduction

Alzheimer's Disease - Overview

Alzheimer's Disease - Therapeutics Development

Alzheimer's Disease - Therapeutics Assessment

Alzheimer's Disease - Companies Involved in Therapeutics Development

Alzheimer's Disease - Drug Profiles

Alzheimer's Disease - Dormant Projects

Alzheimer's Disease - Discontinued Products

Alzheimer's Disease - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Alzheimer's Disease, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..10), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..11), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..12), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..13), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..14), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..15), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..16), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..17), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..18), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..19), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..20), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Products under Development by Companies, H1 2020 (Contd..5), H1 2020  
Products under Development by Companies, H1 2020 (Contd..6), H1 2020  
Products under Development by Companies, H1 2020 (Contd..7), H1 2020  
Products under Development by Companies, H1 2020 (Contd..8), H1 2020  
Products under Development by Companies, H1 2020 (Contd..9), H1 2020  
Products under Development by Companies, H1 2020 (Contd..10), H1 2020  
Products under Development by Companies, H1 2020 (Contd..11), H1 2020  
Products under Development by Companies, H1 2020 (Contd..12), H1 2020  
Products under Development by Companies, H1 2020 (Contd..13), H1 2020  
Products under Development by Companies, H1 2020 (Contd..14), H1 2020  
Products under Development by Companies, H1 2020 (Contd..15), H1 2020  
Products under Development by Companies, H1 2020 (Contd..16), H1 2020  
Products under Development by Companies, H1 2020 (Contd..17), H1 2020  
Products under Development by Companies, H1 2020 (Contd..18), H1 2020  
Products under Development by Companies, H1 2020 (Contd..19), H1 2020  
Products under Development by Companies, H1 2020 (Contd..20), H1 2020  
Products under Development by Companies, H1 2020 (Contd..21), H1 2020  
Products under Development by Companies, H1 2020 (Contd..22), H1 2020  
Products under Development by Companies, H1 2020 (Contd..23), H1 2020  
Products under Development by Companies, H1 2020 (Contd..24), H1 2020  
Products under Development by Companies, H1 2020 (Contd..25), H1 2020  
Products under Development by Companies, H1 2020 (Contd..26), H1 2020  
Products under Development by Companies, H1 2020 (Contd..27), H1 2020  
Products under Development by Companies, H1 2020 (Contd..28), H1 2020  
Products under Development by Companies, H1 2020 (Contd..29), H1 2020  
Products under Development by Companies, H1 2020 (Contd..30), H1 2020  
Products under Development by Companies, H1 2020 (Contd..31), H1 2020  
Products under Development by Companies, H1 2020 (Contd..32), H1 2020  
Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..5), H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..6), H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..7), H1 2020



Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..8), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..9), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..10), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..6), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..7), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..8), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..9), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..10), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Alzheimer's Disease - Pipeline by 1st Bio Therapeutics Inc, H1 2020

Alzheimer's Disease - Pipeline by 2A Pharma AB, H1 2020

Alzheimer's Disease - Pipeline by 4D Pharma Plc, H1 2020

Alzheimer's Disease - Pipeline by 4P-Pharma SAS, H1 2020

Alzheimer's Disease - Pipeline by AB Science SA, H1 2020

Alzheimer's Disease - Pipeline by Abaxy Spri, H1 2020

Alzheimer's Disease - Pipeline by AbbVie Inc, H1 2020

Alzheimer's Disease - Pipeline by AC Immune SA, H1 2020

Alzheimer's Disease - Pipeline by Acelerox LLC, H1 2020

Alzheimer's Disease - Pipeline by Acelot Inc, H1 2020

Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H1 2020

Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H1 2020

Alzheimer's Disease - Pipeline by AcuraStem Inc, H1 2020

Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2020

Alzheimer's Disease - Pipeline by Adocia SAS, H1 2020



Alzheimer's Disease - Pipeline by ADRx Inc, H1 2020  
Alzheimer's Disease - Pipeline by Aerobyx LLC, H1 2020  
Alzheimer's Disease - Pipeline by AfaSci Inc, H1 2020  
Alzheimer's Disease - Pipeline by Affichem SA, H1 2020  
Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2020  
Alzheimer's Disease - Pipeline by Aibios Co Ltd, H1 2020  
Alzheimer's Disease - Pipeline by Alector Inc, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Alzheimer's Disease, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

1st Bio Therapeutics Inc  
2A Pharma AB  
4D Pharma Plc  
4P-Pharma SAS  
AB Science SA  
Abaxy Sprl  
AbbVie Inc  
AC Immune SA  
Acelerox LLC  
Acelot Inc  
Actinogen Medical Ltd  
Acumen Pharmaceuticals Inc  
AcuraStem Inc  
Addex Therapeutics Ltd  
Adocia SAS  
ADRx Inc  
Aerobyx LLC  
AfaSci Inc  
Affichem SA  
AFFiRiS AG  
Aibios Co Ltd

Alector Inc  
AlfaSigma SpA  
Alion Pharmaceuticals Inc  
Alkahest Inc  
Alkermes Plc  
ALS Biopharma LLC  
Alsonex Pty Ltd  
ALSP Inc  
Alzamend Neuro Inc  
AlzeCure Pharma AB  
Alzheon Inc  
Alzhyme Pty Ltd  
Alzinova AB  
AlzProtect SAS  
Alzyn LLC  
Amarantus Bioscience Holdings Inc  
Amylon LLC  
Amylyx Pharmaceutical Corp  
Anavex Life Sciences Corp  
Ankar Pharma SL  
Annovis Bio Inc  
Antoxerene Inc  
Anven AlzDx Inc  
Aphios Corp  
Apodemus AB  
Apollo Therapeutics LLC  
Applied Research using OMIC Sciences SL  
Aprinoia Therapeutics Inc  
AptaBio Therapeutics Inc  
Araclon Biotech SL  
Archer Pharmaceuticals Inc  
AriBio  
ArmaGen Inc  
Armgo Pharma Inc  
Artery Therapeutics Inc  
Arvinas Inc  
Asceneuron SA  
Asdera LLC  
AskAt Inc

Asklepios BioPharmaceutical Inc  
Astellas Pharma Inc  
AstraZeneca Plc  
Astrocyte Pharmaceuticals Inc  
Athira Pharma Inc  
ATP Biopharm  
Augustus BioTarget Inc  
Auransa Inc  
Aurin Biotech Inc  
Auritec Pharmaceuticals Inc  
Autifony Therapeutics Ltd  
Autophagy Neurotherapeutics Inc  
Avanti Biosciences Inc  
Avidin Ltd  
Avineuro Pharmaceuticals Inc  
Axon Neuroscience SE  
Axxam SpA  
AZTherapies Inc  
BCWorld Pharm Co Ltd  
Beactica AB  
Berg LLC  
BeyondBio Inc  
Bio-Pharm Solutions Co Ltd  
BioArctic AB  
Biogen Inc  
Biohaven Pharmaceutical Holding Company Ltd  
Biorchestra Ltd  
BioXcel Therapeutics Inc  
Boehringer Ingelheim International GmbH  
Bolder Biotechnology Inc  
Boryung Pharmaceutical Co Ltd  
Brainvectis SAS  
Bristol-Myers Squibb Co  
BSIM Therapeutics SA  
Cantabio Pharmaceuticals Inc  
Capo Therapeutics Inc  
Carna Biosciences Inc  
Cassava Sciences Inc  
CavoGene LifeSciences

CellCure  
Celon Pharma SA  
Cenna Biosciences Inc  
Cennerv Pharma (S) Pte Ltd  
Center Laboratories Inc  
CerebraMed  
Cerebrum Therapeutics Inc  
Cerecin Inc  
Cesa Alliance SA  
CHA Bio & Diostech Co Ltd  
Changchun Huayang High-Tech Co Ltd  
Chaperone Therapeutics Inc  
Chong Kun Dang Pharmaceutical Corp  
Clayton Biotechnologies Inc  
Clera Inc  
CMG Pharmaceutical Co Ltd  
Cogentis Therapeutics Inc  
Cognition Therapeutics Inc  
Cognosci Inc  
CohBar Inc  
Collaborations Pharmaceuticals Inc  
Collaborative Medicinal Development LLC  
CoPlex Therapeutics LLC  
Corium, Inc.  
Cortexyme Inc  
Cortice Biosciences Inc  
Cotinga Pharmaceuticals Inc  
Covalent Bioscience Inc  
Crossbeta Biosciences BV  
CuroNZ Ltd  
Cyclerion Therapeutics Inc  
Cyclo Therapeutics Inc  
Daewoong Pharmaceutical Co Ltd  
DanPET AB  
DegenRx BV  
Denali Therapeutics Inc  
Denovo Biopharma LLC  
Diffusion Pharmaceuticals Inc  
Dong Wha Pharma Co Ltd

Dong-A ST Co Ltd  
DongKoo Bio & Pharma Co Ltd  
Dongkook Pharmaceutical Co Ltd  
E-scape Bio Inc  
EastGate Pharmaceuticals Inc  
Eikonizo Therapeutics Inc  
EIP Pharma LLC  
Eisai Co Ltd  
Eleusis Ltd  
Elevian Inc  
Eli Lilly and Co  
Elixirgen Therapeutics LLC  
Emerald Organic Products Inc  
EmphyCorp Inc  
Endece LLC  
Enterin Inc  
Epigen Biosciences Inc  
Eptracker Inc  
Everfront Biotech Inc  
F. Hoffmann-La Roche Ltd  
Fortuna Fix Inc  
Fujifilm Toyama Chemical Co Ltd  
GABA Therapeutics Inc  
Gabaeron Inc  
Galimedix Therapeutics Ltd  
GemVax & KAEL Co Ltd  
Genentech Inc  
Genervon Biopharmaceuticals LLC  
GeneScience Pharmaceuticals Co Ltd  
Genuv Inc  
Gismo Therapeutics Inc  
GlaxoSmithKline Plc  
GliaCure Inc  
Gialogix Inc  
Glycadia Inc  
GMP BIO Co Ltd  
GNT Pharma Co Ltd  
Golden Biotechnology Corp  
Grespo AB

Grifols SA  
Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd  
GYRUS Pharmaceuticals Inc  
H. Lundbeck AS  
Halo Mountain LLC  
Hana Pharm Co Ltd  
HEC Pharm Co Ltd  
HitGen LTD  
Hope Biosciences LLC  
HSRx Group  
Hyundai Pharmaceutical Co Ltd  
ICB International Inc  
Icure Pharmaceutical Inc  
IFM Therapeutics LLC  
Imago Pharmaceuticals Inc  
Immugenetics AG  
ImmunoBrain Checkpoint Inc  
ImmunoChem Therapeutics LLC  
Immunwork Inc  
ImStar Therapeutics Inc  
Inflazome Ltd  
Inmune Bio Inc  
InnoBioscience LLC  
Innosense LLC  
Innovimmune Biotherapeutics Inc  
Instituto Biomar SA  
Insys Therapeutics Inc  
IntelGenx Corp  
Intra-Cellular Therapies Inc  
IntraBio Ltd  
Invisio Ltd  
Io Therapeutics Inc  
Ionis Pharmaceuticals Inc  
Jace Biomedical Inc  
Jiangsu Kangyuan Pharmaceutical Co Ltd  
Jiangsu Kanion Pharmaceutical Co Ltd  
Johnson & Johnson  
Jupiter Orphan Therapeutics Inc  
K-Stemcell Co Ltd



Kalgene Pharmaceuticals Inc  
Karuna Therapeutics Inc  
Keypharma Biomedical Inc  
Keystone Bio Inc  
Kine Sciences  
KinoPharma Inc  
Klogene Therapeutics Inc  
Kogenix Therapeutics Inc  
Kordate Solutions Inc  
Kyowa Kirin Co Ltd  
LA Cell Inc  
Lauren Sciences LLC  
Lead Discovery Center GmbH  
Les Laboratoires Servier SAS  
Libella Gene Therapeutics  
Lipopharma Therapeutics SL  
Longeveron LLC  
Lyndra Inc  
Madera BioSciences Inc  
Magnolia Neurosciences Corp  
ManRos Therapeutics  
Med-Life Discoveries LP  
MedaRed Inc  
MedDay SA  
Medesis Pharma SA  
MEDRx Co Ltd  
MeiraGTx Holdings Plc  
Mercia Pharma Inc  
Merck & Co Inc  
Metabolic Solutions Development Company LLC  
MetiMedi Pharmaceuticals Co Ltd  
MetrioPharm AG  
MetVital Inc  
MGC Pharmaceuticals Ltd  
MindImmune Therapeutics Inc  
Mission Therapeutics Ltd  
Mitoconix Bio Ltd  
Modag GmbH  
Montisera Ltd

NAL Pharmaceuticals Ltd  
Nanjing Sanhome Pharmaceutical Co Ltd  
Nanna Therapeutics Ltd  
Nanomerics Ltd  
NatureWise Biotech & Medicals Corp  
NeoCytex Biopharma Inc  
NeoNeuro SAS  
Nerve Access Inc  
NeuExcell Therapeutics Inc  
Neuracle Science Co Ltd  
Neuraly Inc  
Neurim Pharmaceuticals Ltd  
Neurimmune Holding AG  
Neuro Bio Ltd  
Neuro-Sys SAS  
NeuroActiva Inc  
Neurodegeneration Therapeutics Inc  
Neurodon LLC  
Neurodyn Life Sciences Inc  
NeuroGeneration Inc  
NeuroGenetic Pharmaceuticals Inc  
Neurokine Therapeutics  
NeuroLucent Inc  
NeuroNascent Inc  
NeurOp Inc  
Neuropore Therapies Inc  
NeuroScientific Biopharmaceuticals Ltd  
NeuroSolis Inc  
Neurotez Inc  
NeuroTherpia Inc  
Neurotrope Bioscience Inc  
New World Laboratories Inc  
NKMAX Co Ltd  
NoNO Inc  
Novartis AG  
NovMetaPharma Co Ltd  
Novoron Bioscience Inc  
Oleolive LLC  
Oligomerix inc

OncoSynergy Inc  
Ono Pharmaceutical Co Ltd  
Orphi Therapeutics Inc  
Oryzon Genomics SA  
OTR3 SAS  
Ovensa Inc  
Overseas Pharmaceuticals Ltd  
Oxstem Ltd  
P2D Inc  
Panorama Research Inc  
Park Active Molecules  
Partner Therapeutics Inc  
Peptron Inc  
Pharmasum Therapeutics AS  
Pharmatrophix Inc  
Pharmazz Inc  
Pharnext SA  
Phenoquest AG  
Phoenix Biotechnology Inc  
Phoenix Life Sciences International Ltd  
Plico Biotech Inc  
Polaryx Therapeutics Inc  
Prevacus Inc  
Priavoid GmbH  
Prilenia Therapeutics Development Ltd  
Proclara Biosciences Inc  
Progenra Inc  
ProMIS Neurosciences Inc  
Proteome Sciences Plc  
Prothena Corp Plc  
Protheragen Inc  
Prous Institute for Biomedical Research SA  
Providya LLC  
Provention Bio Inc  
PTC Therapeutics Inc  
Quimatryx SL  
Recombinant Technologies LLC  
Regenacy Pharmaceuticals LLC  
Regenera Pharma Ltd

reMYND NV  
ReNetX Bio  
Resilio Therapeutics LLC  
Retrotape Inc  
Revaluesio Corp  
Revivo Therapeutics Inc  
Rodos BioTarget GmbH  
Sage Therapeutics Inc  
Samjin Pharm Co Ltd  
Samumed LLC  
Samus Therapeutics LLC  
SanBio Inc  
Sangamo Therapeutics Inc  
Sanofi  
SBI Pharmaceuticals Co Ltd  
Scientus Pharma Inc  
Selonterra Inc  
Seneca Biopharma Inc  
Sentinel Oncology Ltd  
Serometrix LLC  
SevenGenes Inc  
Shanghai Angecon Biotechnology Corp  
Shanghai Green Valley Pharmaceutical Co Ltd  
Shanghai Rixin Biological Co Ltd  
Shanghai SIMR Biotech Co Ltd  
Shaperon Inc  
Shionogi & Co Ltd  
Simcere Pharmaceutical Group  
Siragen Pharmaceuticals Inc  
Smart Biomolecules Inc  
Sosei Heptares  
SparkBioPharma Inc  
Spherium Biomed SL  
Spinogenix Inc  
Starwise Therapeutics LLC  
Stream Biomedical Inc  
Sunovion Pharmaceuticals Inc  
Suven Life Sciences Ltd  
SynapTEX LLC

T3D Therapeutics Inc  
Taho Pharmaceuticals Ltd  
Takeda Pharmaceutical Co Ltd  
TauC3 Biologics Ltd  
TauRx Therapeutics Ltd  
Techfields Pharma Co Ltd  
TechnoPhage SA  
Teikoku Pharma USA Inc  
Telocyte LLC  
Tetra Therapeutics  
Tetraneuron SL  
Thera Neuropharma Inc  
Tiantai Medical Technology Pty Ltd  
Tonix Pharmaceuticals Holding Corp  
Tranquis Therapeutics Inc  
Treeway BV  
Trementis Corp  
Tria Bioscience Corp  
UCB SA  
United Neuroscience Ltd  
Vaccinex Inc  
Vanworld Pharmaceutical (Rugao) Company Ltd  
Varinel Inc  
Velacor Therapeutics Pty Ltd  
VFP Therapies  
Videns Incorp Ltd  
Virobay Inc  
Virogenics Inc  
Vitruvian Biomedical Inc  
Vivoryon Therapeutics AG  
Vivreon Biosciences LLC  
Voronoi  
Voyager Therapeutics Inc  
vTv Therapeutics Inc  
Vybion Inc  
Wayshine Biopharma Inc  
Xcelthera INC  
Xenexus Pharmaceuticals Pty Ltd  
Xigen SA

Xonovo Inc  
Yasham P2D Lifesciences Pvt Ltd  
Yuma Therapeutics Corp  
Yumanity Therapeutics  
Zensun (Shanghai) Sci & Tech Co Ltd  
Zhejiang Hisun Pharmaceutical Co Ltd  
Zhejiang Huahai Pharmaceutical Co Ltd  
ZZ Biotech LLC

## I would like to order

Product name: Alzheimer's Disease - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/A987E347D4BEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A987E347D4BEN.html>